New drug combo targets genetic fatty liver in Mid-Stage trial
NCT ID NCT07527910
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2a trial is testing a new drug called ALN-PNP, alone or with a weight-loss drug (tirzepatide), in 204 adults with a specific genetic form of fatty liver disease (MASLD). The goal is to see if lowering a certain liver protein can reduce liver fat. Participants must have a high liver fat level and a specific gene variant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALN-PNP (a drug that lowers a protein linked to liver fat) and tirzepatide (a weight and blood sugar control drug)
What this could lead to
If successful, this could point toward a new treatment option for people with a genetic form of fatty liver disease, potentially reducing liver fat and improving liver health.
What could go wrong
This is an early Phase 2 trial with only 204 participants, so results may not apply to everyone. The drug may cause side effects or fail to reduce liver fat significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advanced Medical Trials
RECRUITINGGeorgetown, Texas, 78628, United States
-
American Research Corporation at The Texas Liver Institute
RECRUITINGSan Antonio, Texas, 78215, United States
-
California Liver Research Institute
RECRUITINGPasadena, California, 91105, United States
-
Southern California Research Center
RECRUITINGCoronado, California, 92118, United States
-
Tandem Clinical Research, Plaza II
RECRUITINGMetairie, Louisiana, 70006, United States